CSL Limited operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares CSL Limited with three other
miscellaneous service companies in Australasia:
sales of 18.61 million Australian Dollars [US$14.49 million]
of which 88%
was Drug discovery and development),
Xrf Scientific Ltd
(21.54 million Australian Dollars [US$16.78 million]
of which 40%
was Precious Metals), and
Sirtex Medical Limited
(234.28 million Australian Dollars [US$182.46 million]
of which 86%
CSL Limited reported sales of A$9.20 billion (US$7.16 billion)
June of 2017.
increase of 9.1%
versus 2016, when the company's sales were A$8.43 billion.
Sales at CSL Limited have increased during each of the previous five years
(and since 2012, sales have increased a total of 107%).
Sales of Seqirus saw an increase
15.5% in 2017, from
A$896.87 million to A$1.04 billion.